Mersana Therapeutics (MRSN) Tops Q4 EPS by 4c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $16.36 million versus the consensus estimate of $7.38 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Paramount Weighs Tapping Musk For Equity Investment - Semafor
• Costco (COST) call put ratio 1.5 calls to 1 put into quarter results
• Senior Iranian Official To Reuters: Tehran Is Reviewing U.S. Response To Its Proposal To End Hostilities